Long-Term Investor Stock Analysis of Glaxo Smith Kline (GSK)Read More »
This content is restricted to site members. If you are an existing user, please log in. New users may register below.
Long-Term Investor Stock Analysis of Glaxo Smith Kline (GSK)
Views: 363 2025-10-02 GSK is a global biopharma giant specializing in vaccines, specialty medicines, and general pharmaceuticals. It has a long history, broad portfolio, and steady global revenues. It spun off its consumer healthcare arm (Haleon) in 2022, now more focused on pharma & vaccines. Is the business model simple and sustainable?Not “simple” like consumer staples, but sustainable. Patents, R&D, and government contracts in vaccines ensure revenue durability. Does the company have a durable competitive advantage (moat)?Yes. Its moat comes from: Patents & pipeline (vaccines, HIV, oncology) Global scale in distribution Regulatory barriers But weaker compared to Pfizer or Novartis …
